>I think Hospira may have only filed for the 100mg/mL, 3mL vial product.<
If true, this would explain the absence of chatter about the HSP filing. MNTA/Sandoz filed separate ANDA’s for the vials and the syringes, but the syringes are the more important market by a wide margin.
The above doesn’t change the supposition from my previous post that HSP is fronting for a foreign company which has done some work characterizing Lovenox.
>I get my information from Newport Horizons.<
Can you elaborate on the intelligence they provide? T.i.a.
p.s. Do you have any comment on the postscript in my previous post?
Market Data 
Markets 
AI
